References
- Sanchez Carazo JL, Mahiques Santos L, Oliver Martinez V. Safety of etanercept in psoriasis: a critical review. Drug Saf. 2006;29(8) : 675–85.
- Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001;57(10):1885–8.
- Enayati PJ, Papadakis KA. Association of antitumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol. 2005;39(4):303–6.
- Richez C, Blaco P, Lagueny A, Schaeverbeke T, Dehais J. Neuropathy resembling CIPD in patients receiving tumor necrosis factor-alpha blockers. Neurology. 2005;64(8):1468–70.
- Yamamoto M, Takahashi H, Wakasugi H, Sukawa Y, Saito M, Suzuki C, et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol. 2007;17:72–4.
- Sukal SA, Nadiminti L, Granstein RD. Etanercept and demye-linating disease in a patient with psoriasis. J Am Acad Dermatol. 2006;54:160–4.
- Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor a therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862–9.
- Cay HF, Gungor HA, Sezer I, Kacar C, Balci N. Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report. J Clin Pharm Ther. 2006;31(6):645–8.
- Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor a antagoism: By what mechanisms could tumor necrosis factor a antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum. 2001;44 (9):1977–83.
- Tanaka M, Tanaka K, Komori M, Saida T. Anti-aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibody. J Neurol Neurosurg Psychiatry. 2007;78:990–2.
- Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol. 2004;22:134–40.